Plain-English translation of NCT04115163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to give two chemotherapy drugs— and —to people with pancreatic cancer that has spread beyond the pancreas. Instead of the standard dosing schedule, researchers are trying a different timing to see if it works better and causes fewer side effects. The study wants to measure how well the treatment works and how safe it is for patients.
Metastatic pancreatic cancer is very serious, and current treatments don't work well enough for many patients. This study explores whether changing when and how often patients receive this medication might improve outcomes and make the treatment easier to tolerate.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the two chemotherapy drugs through an IV (intravenous infusion) on specific days within each 28-day cycle: on days 1 and 15, and on days 3 and 17. Each infusion takes about 30 minutes. You will continue this treatment schedule for as long as it is working and you are tolerating it well. After your treatment ends, you'll have follow-up appointments monthly for 3 months, and then every 3 months after that, so the research team can monitor how you're doing.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States